metformin has been researched along with paclitaxel in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (8.16) | 29.6817 |
| 2010's | 37 (75.51) | 24.3611 |
| 2020's | 8 (16.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, C; Liu, J; Tang, J; Wu, F | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hirsch, HA; Iliopoulos, D; Struhl, K | 1 |
| Apontes, P; Blagosklonny, MV; Demidenko, ZN; Leontieva, OV; Li, F | 1 |
| Carvalheira, JB; Dias, MM; Osório-Costa, F; Rocha, GZ; Ropelle, ER; Rossato, FA; Saad, MJ; Vercesi, AE | 1 |
| Bae-Jump, VL; Gehrig, PA; Hanna, RK; Malloy, KM; Sun, L; Zhong, Y; Zhou, C | 1 |
| Dong, L; Duan, T; Feng, Y; Zhang, Z; Zhou, Q; Zhu, Y | 1 |
| Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Lin, YW; Tseng, SC; Weng, SH; Wo, TY | 1 |
| Akahori, H; Finn, AV; Habib, A; Karmali, V; Pachura, K; Polavarapu, R | 1 |
| Amanpour, S; Behrouzi, B; Khorgami, Z; Muhammadnejad, S; Sadighi, S | 1 |
| Chen, F; Lipinski, MJ; Pendyala, LK; Torguson, R; Waksman, R | 1 |
| Li, X; Lu, X; Zhang, M | 1 |
| Cleeland, C; Heijnen, CJ; Huo, XJ; Kavelaars, A; Krukowski, K; Mao-Ying, QL; Price, TJ; Zhou, W | 1 |
| Kaddis, N; Saif, MW | 1 |
| Bradaric, M; Johnson, A; Lee, W; Lengyel, E; Litchfield, LM; Mitra, AK; Mukherjee, A; Nieman, KM; Romero, IL; Zhang, Y | 1 |
| Berbée, M; Buijsen, J; Houben, R; Janssen, L; Lambin, P; Larue, R; Schraepen, MC; Sosef, M; Van De Voorde, L; Vanneste, B | 1 |
| Kumar, L; Patel, S; Singh, N | 1 |
| Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Wu, X | 1 |
| Asik, A; Balcı Okcanoglu, T; Biray Avci, C; Dogan Sigva, ZO; Gunduz, C; Kayabasi, C; Ozmen Yelken, B; Saydam, G; Yılmaz Susluer, S | 1 |
| Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X | 1 |
| Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG | 1 |
| Dahlberg, SE; Kravets, S | 1 |
| Wang, S; Xiao, Y; Yin, Z; Zong, Q | 1 |
| Huang, ZL; Jia, LF; Li, XM; Shan, S; Zhou, CY | 1 |
| Bishnu, A; Chaudhury, K; Choudhury, P; Ghosh, N; Ray, P; Sakpal, A | 1 |
| Cai, H; Everett, RS; Thakker, DR | 1 |
| Liu, Y; Sun, H; Zhang, H; Zheng, Y; Zhu, J | 1 |
| Chatsudthipong, V; Jinakote, M; Ontawong, A; Pasachan, T; Pimta, J; Soodvilai, S; Srimaroeng, C | 1 |
| Broekman, KE; Gietema, JA; Hof, MAJ; Jalving, M; Lefrandt, JD; Nijman, HW; Reyners, AKL; Touw, DJ | 1 |
| Chen, H; Li, J; Li, P; Liu, J; Liu, P; Miao, Y; Wang, R | 1 |
| Wang, B; Wang, Y; Yu, Z; Zhai, J | 1 |
| Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV | 1 |
| Lee, Y; Park, D | 1 |
| Tossetta, G | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
4 review(s) available for metformin and paclitaxel
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Ovarian Neoplasms; Paclitaxel | 2022 |
3 trial(s) available for metformin and paclitaxel
| Article | Year |
|---|---|
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2018 |
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Progression-Free Survival; Prospective Studies; Signal Transduction | 2019 |
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2020 |
42 other study(ies) available for metformin and paclitaxel
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
Topics: Acetates; alpha-Glucosidases; Animals; Antineoplastic Agents; Cell Line, Tumor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Neoplasms; Rats; Solanaceous Alkaloids; Structure-Activity Relationship | 2016 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Metformin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytoprotection; Epithelial Cells; Fibroblasts; G1 Phase; Humans; Imidazoles; Metformin; Nocodazole; Paclitaxel; Piperazines; Sirolimus; Tumor Suppressor Protein p53 | 2011 |
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Drug Synergism; Enzyme Activation; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, SCID; Neoplasms; Paclitaxel; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Metformin; Paclitaxel; RNA, Messenger; Signal Transduction; Telomerase; TOR Serine-Threonine Kinases | 2012 |
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Evaluation, Preclinical; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Lactoylglutathione Lyase; Metformin; Paclitaxel | 2012 |
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; p38 Mitogen-Activated Protein Kinases; Paclitaxel; RNA, Messenger; Up-Regulation | 2013 |
Metformin impairs endothelialization after placement of newer generation drug eluting stents.
Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Hypoglycemic Agents; Iliac Artery; Immunosuppressive Agents; Male; Metformin; Paclitaxel; Rabbits; Sirolimus; Thrombosis; Tubulin Modulators | 2013 |
Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; MCF-7 Cells; Metformin; Paclitaxel | 2014 |
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Male; Metformin; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Stents; Thrombosis | 2014 |
[Metformin inhibits the proliferation of hypopharyngeal carcinoma Fadu cells and enhances the chemotherapeutic sensitivity of cells].
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Humans; Hypopharyngeal Neoplasms; Metformin; Paclitaxel | 2014 |
The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model.
Topics: Animals; Cisplatin; Disease Models, Animal; Hyperalgesia; Hypoglycemic Agents; Metformin; Mice, Inbred C57BL; Nerve Fibers; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Protective Agents | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Metformin; Mice; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Diabetes Mellitus, Type 2; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Metformin and epithelial ovarian cancer therapeutics.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2015 |
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS.
Topics: Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Metformin; Neoplasm Invasiveness; Paclitaxel; Stomach Neoplasms; Time Factors | 2017 |
Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Metformin; NF-kappa B; Oxides; Paclitaxel; Signal Transduction | 2018 |
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Survival Rate | 2018 |
Interpretation of Results from Under-accruing Studies.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Paclitaxel | 2018 |
Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Metformin; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
[Metformin's effect on 5-fluorouracil,cisplatin,paclitaxel in laryngocarcinoma Hep-2 cells].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Fluorouracil; Humans; Hypoglycemic Agents; Laryngeal Neoplasms; Metformin; Paclitaxel | 2017 |
Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
Topics: Amino Acids; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Metformin; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Taurine; Time Factors | 2019 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Drug Synergism; Female; Humans; Hypoglycemic Agents; Mammary Neoplasms, Experimental; Metformin; Mice, Nude; Organic Cation Transport Proteins; Paclitaxel; Tumor Burden | 2019 |
High affinity of 4-(4-(dimethylamino)styryl)-N-methylpyridinium transport for assessing organic cation drugs in hepatocellular carcinoma cells.
Topics: Biological Transport; Carcinoma, Hepatocellular; Cations; Cell Line, Tumor; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Metformin; Organic Cation Transporter 1; Organic Cation Transporter 2; Paclitaxel; Pyridinium Compounds | 2020 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Hippo Signaling Pathway; Humans; MAP Kinase Kinase Kinases; Membrane Proteins; Metformin; Mice, Inbred BALB C; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Serine-Threonine Kinases; Protein Transport; Signal Transduction; Tamoxifen; Transcription Factors; Tumor Suppressor Proteins; YAP-Signaling Proteins | 2020 |
Metformin Affects Paclitaxel Sensitivity of Ovarian Cancer Cells Through Autophagy Mediated by Long Noncoding RNASNHG7/miR-3127-5p Axis.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Long Noncoding; Up-Regulation | 2022 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, Type 2; Doxorubicin; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; MCF-7 Cells; Metformin; Mice, Inbred NOD; Mice, SCID; Neoplasms; Paclitaxel | 2021 |
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Melanoma; Metformin; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms | 2021 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell Line, Tumor; Drug Synergism; Humans; Metformin; Neoplasm Recurrence, Local; Paclitaxel | 2022 |